Catastrophic antiphospholipid syndrome (CAPS): A rare and fatal encounter
Sir, Antiphospholipid syndrome (APS) is a rare, multisystem, autoimmune, hypercoagulable disorder caused by production of antibodies against cell membrane made up of phospholipids, which will cause venous and/or arterial thromboembolism that can become disastrous if multi organ failure develops. We report a case of catastrophic variant of APS with good outcome. Patient developed pulmonary and peripheral vessels thrombosis in spite of anticoagulant and antiplatelet agents that was treated by surgical intervention which is reported in very few cases.
A 35-year-old female obese (102 kg) patient, without any bad obstetric history or other co-morbidities except 1 st time detected diabetes mellitus, admitted for acute left middle cerebral artery infarct at peripheral hospital. She was not thrombolysed there because of late presentation. She was discharged after 2 days with improved limb weakness and was on subcutaneous low-molecular-weight heparin at home for 3 more days [ Figure 1 ].
She developed breathlessness on exertion 2 days after discharge. She was diagnosed to have bilateral massive pulmonary embolism with respiratory failure, so referred to our hospital for further management.
She was not thrombolysed for pulmonary embolism because of recent cerebral vascular stroke. She was put on Bipap ventilator support and given heparin and supportive treatments. She also diagnosed to have right popliteal vein thrombosis on Doppler examination after admission to our hospital.
Subsequently ventilator requirement increased and she was not maintaining oxygen saturation with 100% FiO 2 and 15 positive end-expiratory pressure. So decided for surgical embolectomy by thoracovascular surgeon. When surgical preparation was going on, she developed right lower limb femoral arterial thrombosis also. Hence, it was operated first followed by pulmonary embolectomy (thrombectomy). Postoperatively oxygen requirement decreased to minimal on ventilator with good femoral arterial flow also.
However, she developed severe sepsis, septic shock and acute renal failure postoperatively, which was treated accordingly. After stabilization, she was weaned from ventilator support and shifted to the ward. She was discharged on day-22. Considering multiple arterial/venous thromboembolic events, APS work up was done, which came positive. And according to criteria that was a catastrophic variant. [1] After 3 months of follow-up, again antiphospolipid antibodies sent, which came positive. So diagnosis was confirmed. [2] Our patient developed multiple thrombotic events within a span of 1-week. We suspect APS initially and taken prompt actions particularly for pulmonary and femoral arterial thrombosis. We succeeded in tackling both the life threatening events of thrombosis with the help of vascular surgeon. In selected/resistant cases, immunosuppresion with Figures 1 and 2] . All peripheral pulses were palpable and color Doppler of upper and lower limb vessels indicated normal flow. Investigations revealed hemoglobin 10.9 g/dL, platelet count 44,000 cells/mm 3 , PT INR 1.72, low antithrombin-lll levels and deranged liver function. Plasma was positive for fibrin degradation products and D-dimers. She was shifted to Intensive Care Unit suspecting septic shock and resuscitated with intravenous (IV) fluids and dopamine infusion. In view of persisting hypotension and desaturation, she was intubated and mechanically ventilated. Unfractionated heparin was started to treat digital gangrene, attributing it to the pro-thrombotic state of sepsis. She developed bleeding per vaginally and orally in course of 2 days while her PT-INR rose to 2.8, platelet count decreased to 11,000 cells/mm 3 and fibrinogen levels were 65 mg/dL, indicative of consumptive coagulopathy. This was treated with transfusion of six units FFP, four units each of cryoprecipitate and platelet, and bleeding was controlled within 2 days.
Letters to the Editor
After 72 h, blood culture was positive for S. pyogenes, sensitive to ceftriaxone, amoxicillin/ampicillin 
